[Microalbuminuria is an early marker for increased morbidity and mortality]

Fortschr Med Orig. 2003 Feb 27:121 Suppl 1:28-32.
[Article in German]

Abstract

Recent studies have shown the beneficial effects of a blockade of the renin-angiotensin system (RAS) not only for blood pressure reduction but also end organ protection. One of the markers that is closely correlated with the increased cardiovascular risk is microalbuminuria. A common mediator for the development of both, microalbuminuria and end organ damage seems to be Angiotensin II, the blockade of which apparently reduces microalbuminuria as well as end organ damage. Therefore we had a closer look into pathophysiology of microalbuminuria and the relevance for end organ damage and discuss current medical strategies to alleviate these diseases.

Publication types

  • English Abstract

MeSH terms

  • Albuminuria / diagnosis
  • Albuminuria / epidemiology
  • Albuminuria / etiology*
  • Albuminuria / physiopathology
  • Angiotensin II / antagonists & inhibitors
  • Angiotensin II / physiology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Biomarkers
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control
  • Clinical Trials as Topic
  • Coronary Disease / etiology
  • Coronary Disease / mortality
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Nephropathies / diagnosis
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / mortality
  • Female
  • Humans
  • Hypertension / complications*
  • Hypertension / drug therapy
  • Hypertension / physiopathology
  • Losartan / therapeutic use
  • Male
  • Meta-Analysis as Topic
  • Prevalence
  • Proteinuria / etiology
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / physiology
  • Risk Factors
  • Stroke / etiology
  • Stroke / mortality

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Biomarkers
  • Angiotensin II
  • Losartan